Kestra Medical Technologies (KMTS) earnings call transcripts

Management framed the quarter as evidence of accelerating market expansion, improving unit economics, and commercial productivity supporting durable growth and operating leverage.

Management framed FY26 as an investment year whose expanded sales force, improving reimbursement execution and clinical evidence support durable growth in an expanding WCD market.

Management framed the quarter as evidence that its commercial buildout and rental economics are beginning to scale, while emphasizing continued investment over near-term profitability.

Management framed Q2 as evidence of accelerating category growth, improving unit economics and clinical evidence that could broaden WCD use, without relying on guideline changes.